Taťána Gazárková is currently a&nbsp;postdoctoral fellow in the Laboratory of Antibiotic Resistance and Microbial Metabolomics. During her doctoral studies, she focused on chromatography and mass spectrometry. Recently, she was awarded second place in the “Sanofi Prize for Pharmacy 2026” competition.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/MBU_AV_CR_Lukas_Biba_Rozhovor_Cim_zaujala_analyticka_chemie_postdoktorandku_Tatanu_Gazarkovou_7450c646fa.jpg" alt="MBÚ/Lukas Biba:&nbsp;Sanofi Prize for Pharmacy 2026" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_MBU_AV_CR_Lukas_Biba_Rozhovor_Cim_zaujala_analyticka_chemie_postdoktorandku_Tatanu_Gazarkovou_7450c646fa.jpg 234w," sizes="100vw" width="1024" height="683">Taťána Gazárková is currently a&nbsp;postdoctoral fellow in the Laboratory of Antibiotic Resistance and Microbial Metabolomics. During her doctoral studies, she focused on chromatography and mass spectrometry. Recently, she was awarded second place in the “Sanofi Prize for Pharmacy 2026” competition, which is awarded by the French Embassy in the Czech Republic for her dissertation – Steroid Analysis Using Modern Chromatographic and Mass Spectrometry Techniques: From Fundamental Studies to Targeted Bioanalytical Applications (supervisor: Lucie Nováková, Charles University).&nbsp;<h5>What makes this field particularly exciting or unique in your view?</h5>What I&nbsp;enjoy about analytical chemistry is that, to a&nbsp;certain extent, it is a&nbsp;kind of detective work. You are often looking for ways to “make the invisible visible”. In other words, extract the information you are interested in from a&nbsp;complex sample and then interpret it correctly. What also appeals to me about bioanalytical chemistry is its interdisciplinary nature. It brings together analytical chemistry, biochemistry, biology and medicine, which means that you need to be able not only to translate a&nbsp;biological or clinical question into a&nbsp;measurable analytical experiment, but also to place the resulting data back into a&nbsp;broader biological context. This combination of different perspectives is probably what I&nbsp;enjoy most about the field. At the same time, there is still plenty of room for fundamental research, ranging from studying analytical techniques themselves and improving them to developing new methodological approaches.<h5>How did you end up at the <a target="_blank" rel="noopener noreferrer" href="https://mbu.cas.cz/en/research/laboratory-of-antibiotic-resistance-and-microbial-metabolomics">Laboratory of Antibiotic Resistance and Microbial Metabolomics</a>, and what project are you currently working on?</h5>I came to the Institute of Microbiology through a&nbsp;joint project between Dr Zdeněk Kameník and Assoc. Prof. Jan Bobek from the First Faculty of Medicine, Charles University. For me, it was also an opportunity to move from targeted analysis and the study of chromatographic techniques towards untargeted metabolomics and new biological questions.In the project, we are trying to identify new biologically active compounds that would be effective, particularly against pathogenic fungi. As a&nbsp;potential source of such compounds, we study streptomycetes, bacteria known for their ability to produce a&nbsp;wide range of biologically active compounds, including many antibiotics that are currently in clinical use. We focus on less-explored host-associated streptomycetes, in which we had already observed antifungal activity in previous experiments. We are especially interested in strains active against Candida albicans whose activity cannot be explained by the presence of a&nbsp;known bioactive compound. These strains may represent an interesting source of novel compounds. We then integrate the results of untargeted metabolomic analyses with genomic analyses, which allows us to obtain a&nbsp;more comprehensive view of the biosynthetic potential of selected strains.<h5>You also took part in this year’s Vědafest, a&nbsp;science outreach event for the public. What was it like?</h5>I already had some experience with science outreach through events such as Researchers’ Night and the Science Fair at my previous institution, but this year’s Vědafest was still new to me in some ways. This time, I&nbsp;was presenting a&nbsp;field that I&nbsp;myself had entered only relatively recently. It was therefore more challenging to find the right analogies and explain the essence of the topic in a&nbsp;way that was simple, yet precise and scientifically accurate. At the same time, that was exactly what made it inspiring. It forces you to look at your own work from a&nbsp;different perspective. What I&nbsp;enjoyed most was the spontaneity and curiosity of the children, who often came up with questions that would never even occur to an adult.<h5>What are the biggest challenges you face on your scientific journey, and what helps you overcome them?</h5>One of the greatest, but at the same time most interesting, challenges is, in my view, the uncertainty that is inseparably linked to research. For a&nbsp;long time, you often do not know whether you have taken the right direction in addressing a&nbsp;particular question or whether you will ultimately manage to find that figurative final piece of the puzzle. At the same time, this uncertainty is precisely what makes science exciting for me.Another major challenge, particularly in interdisciplinary projects, is communication. It is important from the very formulation of a&nbsp;hypothesis and the planning of experiments through to the interpretation of results, including negative ones, and placing them in a&nbsp;broader context. To some extent, every field has its own language, and finding a&nbsp;common understanding is not always straightforward. Personally, I&nbsp;find it very helpful to be able to discuss problems with colleagues on an ongoing basis, whether individually or during regular laboratory seminars. One of the major strengths of our current group is its interdisciplinary nature, which allows me to look at the same problem from several different perspectives. It is also important for me not to lose my curiosity, because that is ultimately what leads us to ask further questions.<h5>What are your plans after completing your PhD?</h5>After finishing my PhD, I&nbsp;decided that I&nbsp;do not need to have everything that comes next precisely mapped out straight away. I&nbsp;would like to keep different options open for a&nbsp;while and continue building on my experience in analytical chemistry, while at the same time connecting it with other areas that have a&nbsp;biological or medical relevance. I&nbsp;believe that we can keep learning throughout our lives, so I&nbsp;am quite curious to see where the next stage of my journey will take me.Thank you for the interview!

Interview: What Drew Postdoc Taťána Gazárková to Analytical Chemistry

Per- and polyfluoroalkyl substances (PFAS) have earned the moniker "forever chemicals" due to their extreme persistence in the environment. Their detection is crucial for protecting public health and the environment as these synthetic compounds continue to pose significant challenges worldwide. This comprehensive exploration examines why PFAS detection matters, current detection methods, and future directions in addressing PFAS contamination.<h3>Understanding PFAS and Their Health Impacts</h3>PFAS are a class of synthetic organic compounds with diverse structures, properties, and uses. Despite their diversity, all PFAS contain perfluoroalkyl moieties that are extremely resistant to environmental and metabolic degradation [1]. This high persistence is a defining characteristic that makes PFAS management particularly challenging.<h3>Documented Health Effects</h3>Current scientific research has linked PFAS exposure to numerous adverse health outcomes:<ul><li>Reproductive effects including decreased fertility and increased high blood pressure in pregnant women [8]</li><li>Developmental effects in children such as low birth weight, accelerated puberty, and behavioral changes [8]</li><li>Reduced immune system function, including decreased vaccine response</li><li>Interference with natural hormones and endocrine disruption</li><li>Increased cholesterol levels and obesity risk</li><li>Increased risk of several cancers, including prostate, kidney, testicular, oral cavity/pharynx, brain, and endocrine cancers [3]</li></ul>A 2023 study linked PFAS-contaminated water with up to a 33% increase in cancer incidence in affected areas [3]. The study compared regions with elevated PFAS levels to cancer data from the National Cancer Institute, finding higher incidences of various cancers after controlling for factors like smoking and obesity.<h3>Environmental Persistence and Contamination</h3>The extreme persistence of PFAS represents a fundamental concern for environmental management. PFAS are considered the most environmentally persistent substances among organic chemicals [7]. This persistence means that even if all PFAS uses were immediately phased out, existing contamination would continue to affect ecosystems and water supplies for generations.A 2023 study at a military fire training site estimated that PFAS contamination will persist for centuries without remediation [7]. The research found that terminal PFAS still exceed regulatory limits by 2000-fold decades after aqueous film-forming foam (AFFF) use ceased, with precursors accounting for around half of the extractable organofluorine across years.<h3>Current Detection Methods</h3><h4>EPA Standardized Methods</h4>The Environmental Protection Agency (EPA) has developed several standardized methods for PFAS detection, each with specific applications and capabilities:<h5>EPA Method 533</h5><a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/epa-533-drying-down-pfas-samples-after-spe">EPA Method 533</a> focuses on "short chain" PFAS with carbon chain lengths of C4 to C12. Released in December 2019, this method complements Method 537.1 and includes several key features:<ul><li>Uses isotope dilution quantification approach with extracted internal standards, which reduces overall analytical uncertainty</li><li>Employs weak anion exchange solid phase extraction cartridges as opposed to polystyrene divinylbenzene used in 537.1</li><li>Can analyze 25 PFAS compounds, including additional short-chain PFAS that were not apart of Method 537.1</li><li>Allows for longer holding times: 28 days to extraction and 28 days to analyze (compared to 14 days to extraction in Method 537.1)</li><li>Uses ammonium acetate as a preservative (versus Trisma in Method 537.1) [1]</li></ul><h5>EPA Method 537/537.1</h5><a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/sample-concentration-epa-method-537-pfas-determination">EPA Method 537 </a>was first published in 2009 for the determination of 14 PFAS in drinking water [6]. It was later updated to Method 537.1 in 2018 (with editorial updates in 2020) to expand its capabilities:<ul><li>Uses<a target="_blank" rel="noopener noreferrer" href="https://www.organomation.com/what-is-solid-phase-extraction-spe"> solid phase extraction (SPE) </a>and<a target="_blank" rel="noopener noreferrer" href="https://www.organomation.com/preparing-samples-for-lc-ms/ms-analysis"> liquid chromatography/tandem mass spectrometry (LC-MS/MS)</a></li><li>Method 537.1 expanded detection to 18 PFAS compounds, including HFPO-DA (one component of GenX technology)</li><li>Utilizes styrene-divinylbenzene (SDVB) media for extraction</li><li>Requires samples to be extracted within 14 days and analyzed within 28 days</li><li>Methanol is used to elute the extracts. This should then be reconstituted with a 96:4 methanol:water mixture [1]</li></ul>Together, Methods 533 and 537.1 can detect a total of 29 unique PFAS compounds in drinking water and are approved for monitoring under the fifth Unregulated Contaminant Monitoring Rule (UCMR 5) and the PFAS National Primary Drinking Water Regulation [1] [3].<h5>EPA Method 1633</h5><a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/preparing-diverse-sample-matrices-for-epa-method-1633">EPA Method 1633</a>, released in 2024, represents a significant advancement in PFAS analysis:<ul><li>Developed for the analysis of 40 PFAS compounds in various matrices, including surface water, groundwater, wastewater, soil, biosolids, sediment, landfill leachate, and fish tissue</li><li>Expands beyond the drinking water focus of Methods 533 and 537.1</li><li>Provides a standardized approach that may replace modified drinking water methods (i.e., modified EPA 537) that were previously used for non-drinking water matrices [1]</li></ul><h4>Conventional Analytical Techniques</h4>The gold standard for PFAS analysis involves chromatographic techniques coupled with mass spectrometry:<ul><li>Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) is the most widely used method for PFAS analysis, offering high sensitivity and specificity [1]</li><li>High-Resolution Mass Spectrometry (HRMS) allows for rapid detection and identification of PFAS species at very low concentrations [5]</li></ul>These techniques can detect PFAS at parts per trillion (ppt) levels, which is essential given the low concentrations at which PFAS can cause health effects [1]. However, these methods require sophisticated equipment, specialized training, and significant financial resources, making them inaccessible in many regions, particularly in developing countries.<h4>Emerging Detection Technologies</h4>Several innovative approaches are being developed to address the limitations of conventional methods:<ul><li>Electrochemical biosensors using modified electrodes have shown promise for selective PFAS detection with low detection limits [2]</li><li>Surface-Enhanced Raman Spectroscopy (SERS) uses metallic nanoparticles and can be made into a portable method for on-site testing [1]</li><li>Molecular imprinted polymers (MIPs) offer thermal and physical stability, reusability, and low-cost synthesis for PFAS detection [6]</li></ul>These emerging technologies aim to provide more accessible, field-deployable, and cost-effective alternatives to traditional laboratory-based methods.<h3>Challenges in PFAS Detection</h3><h4>Analytical Challenges</h4>Detecting PFAS presents several technical challenges:<ul><li>The ubiquity of PFAS in laboratory equipment and accessories can lead to background contamination when measuring at parts-per-trillion levels [1]</li><li>Many components in liquid chromatographs, mass spectrometers, and solid-phase extraction systems contain materials that can leach PFAS compounds [9]</li><li>The vast number of PFAS (thousands of compounds) makes comprehensive detection difficult, as analytical standards are only available for a small subset [1]</li><li>Complex matrices like food and environmental samples require sophisticated sample preparation techniques</li></ul><h4>Global Disparities in Detection Capabilities</h4>Access to PFAS detection technology varies significantly worldwide:<ul><li>Many developing regions, particularly in Africa, lack adequately equipped laboratories with the necessary instrumentation to detect and measure PFAS</li><li>There is often a scarcity of qualified professionals with experience in PFAS analysis in these regions</li><li>The high cost of acquiring and maintaining sophisticated analytical instruments presents a substantial obstacle to conducting extensive PFAS investigations in resource-limited settings [1]</li><li>Competing priorities such as infectious diseases, poverty, and food security often divert attention and resources from environmental pollutants like PFAS</li></ul><h4>Regulatory Landscape and Compliance</h4>The regulatory framework for PFAS is evolving rapidly worldwide:<ul><li>The EPA finalized Section 8(a)(7) of the Toxic Substances Control Act in September 2024, requiring manufacturers and importers to report on their use of PFAS since 2011 [10]</li><li>Electronic reporting for PFAS will open on July 11, 2025, with final reporting deadlines in 2026</li><li>Companies must report detailed information including chemical identity, production volumes, industrial and consumer products, worker exposure, and disposal methods [10]</li></ul>These regulations are driving demand for more effective and accessible PFAS detection methods to ensure compliance and protect public health.<h3>Future Directions in PFAS Detection</h3><h4>Technological Advancements</h4>The future of PFAS detection lies in developing more accessible, sensitive, and comprehensive methods:<ul><li>Non-targeted screening methods that can identify unknown PFAS compounds without requiring analytical standards for each specific compound</li><li>Total fluorine analysis techniques like Adsorbable Organic Fluorine and Total Oxidizable Precursor Assay that can quantify the presence of fluorine atoms within a sample [1]</li><li>Portable sensors and field-deployable technologies that enable on-site monitoring and rapid response to contamination events</li><li>AI-driven solutions that can improve data analysis and interpretation for complex PFAS mixtures</li></ul><h4>Collaborative Approaches</h4>Addressing the global challenge of PFAS detection requires coordinated efforts:<ul><li>International partnerships between researchers in developed and developing regions to enhance expertise and capacity building</li><li>Standardization of analytical methods to ensure consistency and comparability of results across different laboratories and regions</li><li>Open data sharing and collaboration across countries to leverage collective knowledge and resources</li><li>Integration of PFAS monitoring into broader environmental and public health surveillance systems</li></ul><h3>Conclusion</h3>The detection of PFAS is not merely a technical challenge but a critical public health and environmental imperative [1]. As these "forever chemicals" continue to persist in our environment, developing effective, accessible, and comprehensive detection methods becomes increasingly important. By advancing detection technologies, strengthening regulatory frameworks, and fostering global collaboration, we can better understand, monitor, and ultimately mitigate the impacts of PFAS contamination.The EPA's standardized methods (533, 537.1, and 1633) provide crucial tools for monitoring PFAS in various environmental matrices, but continued innovation is needed to address the full spectrum of PFAS compounds and to make detection more accessible globally [1] [6]. The path forward requires sustained investment in research and development, capacity building in resource-limited settings, and a commitment to environmental justice that ensures all communities have access to the tools and information needed to protect themselves from PFAS exposure. Only through such comprehensive approaches can we hope to address the complex challenges posed by these persistent pollutants.Be sure to check out our other installments of our&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/introducing-our-environmental-contaminants-series-making-sense-of-the-alphabet-soup">Environmental Contaminant Series</a>&nbsp;covering&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/the-importance-of-detecting-persistent-organic-pollutants-pops">Persistent Organic Pollutants (POPs)</a>,&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/the-importance-of-detecting-polycyclic-aromatic-hydrocarbons-pahs">Polycyclic Aromatic Hydrocarbons (PAHs)</a>,&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/the-importance-of-detecting-semi-volatile-organic-compounds-svocs">Semi-Volatile Organic Compounds (SVOCs)</a>, and <a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/the-importance-of-detecting-polychlorinated-biphenyls-pcbs">Polychlorinated Biphenyls (PCBs)</a>.

The Importance of Detecting Per- and Polyfluoroalkyl Substances (PFAS)

Our Library never stops expanding. What are the most recent contributions to LabRulezICPMS Library in the week of 31st August 2026? Check out new documents from the field of spectroscopy/spectrometry and related techniques!<blockquote>👉 <a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/library">SEARCH THE LARGEST REPOSITORY OF DOCUMENTS ABOUT SPECTROSCOPY/SPECTROMETRY RELATED TECHNIQUES</a></blockquote><blockquote>👉 Need info about different analytical techniques? Peek into <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library">LabRulezLCMS</a> or <a target="_blank" rel="noopener noreferrer" href="https://gcms.labrulez.com/library">LabRulezGCMS</a> libraries.</blockquote>This week we bring you brochures by Agilent Technologies and Waters Corporation and application notes by Shimadzu and Thermo Fisher Scientific!<h3>1. Agilent Technologies: Agilent OpenLab ICP-MS Software</h3>Simplify every step of ICP-MS analysisFor Agilent <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/icpms/library?mainauthorItems=10&amp;search=7800">7800</a>, <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/icpms/library?mainauthorItems=10&amp;search=7850">7850</a>, and <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/icpms/library?mainauthorItems=10&amp;search=7900">7900</a> ICP-MS systems, and Agilent <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/icpms/library?mainauthorItems=10&amp;search=8900">8900</a> and <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/icpms/library?mainauthorItems=10&amp;search=9500">9500 ICP-QQQ</a> systems.<ul><li>Brochure</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/br_openlab_icp_ms_software_5994_9288en_agilent_05f01dcdef.pdf">Full PDF for download</a>&nbsp;</li></ul>The brochure introduces <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/icpms/library?mainauthorItems=10&amp;search=OpenLab+ICP-MS+Software">Agilent OpenLab ICP-MS Software</a>, designed to simplify routine operation and data handling for Agilent 7800, 7850, and 7900 ICP-MS systems and the 8900 and 9500 ICP-QQQ systems. The software supports the complete analytical workflow—from checking instrument readiness and creating batches to acquisition, data review, reporting, and compliance. A central dashboard provides an overview of system status, maintenance requirements, instrument health, and utilization, while Smart EMF and post-run performance checks help users identify when maintenance may be required. Guided Diagnostics, Meter Monitor, and time-stamped system records also support troubleshooting by tracking parameters such as vacuum levels, gas flows, and temperatures.Method and batch setup are designed to reduce manual configuration. Batches can be created from preset methods, templates, existing batches, Method Wizard, or Method Advisor, and legacy Agilent ICP-MS MassHunter batches can be opened directly in OpenLab ICP-MS. For the 9500 ICP-QQQ, Method Advisor provides an element-focused approach in which users select target elements and calibration information while the software applies recommended acquisition masses and cell-gas conditions. Preset methods are available for applications including EPA 200.8/EPA 6020, USP &lt;232&gt;, ICH Q3D, and Chinese Pharmacopoeia requirements, while an IntelliQuant Screening preset supports semiquantitative screening of unknown samples. Routine instrument tasks can also be automated through autotuning, startup checks, batch queues, end-of-run verification, rinse functions, and automatic shutdown.For data evaluation, OpenLab ICP-MS provides a real-time workspace where users can review analyte concentrations, internal-standard recoveries, stability plots, spectra or chromatograms, calibration information, QC charts, and IntelliQuant results in a single view. IntelliQuant acquires a complete mass spectrum and displays semiquantitative elemental concentrations using a color-coded periodic table, while IntelliQuant Star Rating assigns a zero-to-five-star data-quality score based on factors such as potential interferences, calibration quality, background, detection limits, and precision. Reporting options include whole-batch reports, elemental impurity reports for USP &lt;232&gt;/&lt;233&gt; and ICH Q3D, customizable reports, structured CSV export, and direct data transfer to LIMS.The software can be expanded for specialized applications, including LC-ICP-MS and GC-ICP-MS, advanced QC workflows, single-particle ICP-MS and FFF-ICP-MS, ADS 2 automation, semiconductor analysis, and peripheral-device control. Supported analytical approaches include external calibration, standard additions, semiquantitative calibration, isotope ratios, and isotope dilution. For regulated laboratories, OpenLab ICP-MS can be combined with scalable OpenLab compliance solutions providing electronic signatures, user access control, configurable roles, system activity logs, and audit trails, supporting workflows subject to 21 CFR Part 11, EU Annex 11, and equivalent regulations. Overall, the platform is positioned as a unified environment for routine and advanced ICP-MS workflows, combining instrument control, method setup, diagnostics, data-quality assessment, reporting, and compliance support.<h3>2. Shimadzu: Identification of Virgin PET and Recycled PET by X-ray Fluorescence Spectrometry</h3><ul><li>Application note</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/an_01_01204_en_f3f20ff020.pdf">Full PDF for download</a></li></ul><h5>User benefits</h5><ul><li>EDX enables the identification of recycled PET.&nbsp;</li><li>Measurements are quick and simple, require no cumbersome pretreatment, and can be automated using a multi-sample turret.&nbsp;</li><li>The instrument offers excellent cost-performance and supports the detection of a wide range of elements.</li></ul>Establishing a sustainable circular economy is a major societal challenge, and recycling plastic materials such as PET (polyethylene terephthalate) plays a particularly important role in reducing environmental impact. Large numbers of PET bottles and molded products are used every day in the food and beverage sectors. To recycle these materials safely and reliably, technologies are required that can accurately identify their origin. In practice, however, appearance and conventional physical properties alone are insufficient to distinguish virgin material from recycled material, creating a need for a more reliable identification method.&nbsp;For rapid identification in industrial settings, a method requiring little or no pretreatment is highly desirable. In some cases, nondestructive analysis is also needed to enable subsequent application of other analytical techniques. This article presents a practical approach in which metal catalysts present in PET are detected by EDX (Energy-Dispersive X-ray Spectroscopy) and used to distinguish material-recycled PET from virgin PET.<h4>Principle and Overview&nbsp;</h4>Metal catalysts such as antimony (Sb) and germanium (Ge) are used in the synthesis of PET resin. These catalyst metals have been reported to be useful indicators of material origin. 1),2) For example, Sb and Ge are frequently detected together in material-recycled PET, whereas only one catalyst metal is detected in chemically recycled PET and virgin PET. This likely reflects the fact that material-recycled PET is derived from a mixture of feedstocks using different catalysts.&nbsp;ICP-AES (ICP optical emission spectrometry) and ICP-MS (ICP mass spectrometry), which are commonly applied to catalyst metal analysis, provide high sensitivity and accuracy. However, they require pretreatment to convert the sample into a solution, thereby lengthening the analytical workflow. By contrast, EDX can measure solid samples directly, making it well-suited to applications requiring rapid results, such as incoming material inspection and in-line analysis in molding plants. Because EDX is non-destructive, it is also suitable for multimodal analytical workflows.&nbsp;On the other hand, some commercially available handheld EDX instruments do not support elements such as Sb and Ge. At the same time, higher-end systems may not offer the specifications or price range needed for industrial deployment. The <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/icpms/library?mainauthorItems=1&amp;search=EDX-7200">EDX-7200</a> supports a broad range of elements with excellent cost performance. This article describes the analysis of Sb and Ge in PET using this instrument.<h4>Conclusion&nbsp;</h4>EDX enables rapid and straightforward elemental analysis without cumbersome sample pretreatment. Previous studies have shown that the presence of Sb and Ge can be used to identify recycled PET. Building on this concept, this article presents a practical analytical approach based on EDX. Using the EDX-7200, which combines broad elemental coverage with excellent cost performance, the proposed method provides a practical tool for rapid on-site identification, quality control, and traceability management. When combined with physical property data and other information, this approach is expected to contribute to the safety assessment and quality assurance of recycled materials, thereby supporting a more advanced circular economy.<h3>3. Thermo Fisher Scientific: Optimizing lithium-ion battery recycling operations using handheld XRF analysis</h3><ul><li>Application note</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/lithium_ion_battery_recycling_handheld_xrf_analysis_an1120_en_4c00477b78.pdf">Full PDF for download</a></li></ul>The shift to a low-carbon economy and the adoption of electric vehicles will drive an exponential increase in the demand for lithium-ion batteries. As a corollary to this, the International Energy Agency expects the demand for some key commodities to increase significantly over the next two decades: the demand for Copper (Cu) is anticipated to increase by more than 40%; for nickel (Ni) and cobalt (Co), by 60-70% each; and for lithium (Li), by nearly 90%.¹ This will translate into increased mining activities and potentially generate larger amounts of deleterious waste.&nbsp;To reduce the environmental impact and limit reliance on scarce commodities associated with economical and geopolitical implications, several countries have implemented regulations regarding producers’ responsibilities.² These regulations contain both incentives and accountability guidelines for lithium-ion battery and electric vehicles manufacturers. Their goal is to facilitate the emergence of a circular economy in which recycling will increasingly contribute to the supply of the strategic raw materials.&nbsp;Lithium-ion batteries are made of multiple components, the most valuable being the cathode that contains between 40 and 70% ³, ⁴ of the total value of the battery, depending on its exact chemistry. As of 2023, lithium nickel cobalt manganese oxides (NCM) account for 66% of lithium-ion battery cathode active materials for electric vehicles, followed by lithium iron phosphates (LFP) which account for 24%, and lithium nickel cobalt aluminum oxide (NCA) accounts for the remaining 10%.³<h4>Handheld X-ray Fluorescence Analysis&nbsp;</h4>Handheld X-ray fluorescence analysis (HHXRF) is an elemental analysis technique that has proven to be cost-effective in recycling areas such as scrap metal and automotive catalytic converters. HHXRF can measure elements from magnesium (Mg) to uranium (U) in various types of materials such as metals and alloys; non-metallic inorganic materials such as ceramics; or ores or plastics. The <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/1993">Thermo Scientific™ Niton™ XL2</a> and <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/1992">Thermo Scientific™ Niton™ XL5 Plus Handheld XRF Analyzers </a>deliver accurate elemental analysis in real time, with little or no sample preparation, across multiple steps of the lithium-ion battery recycling workflow. Although handheld XRF does not detect lithium, it can measure most elements from the periodic table including nickel or cobalt which often command much higher value than the lithium in a lithium-ion battery.⁴<h4>Conclusion&nbsp;</h4>There is no ideal process to recycle lithium-ion batteries that simultaneously incorporates low environmental impact, high metal recovery yield, and economic viability. Because of the variety of technologies and materials used, recycling lithium-ion batteries is a complex journey with multiple possible paths. HHXRF helps recyclers by generating lab-quality data in real time, allowing them to optimize their processes and make fast decisions that generate significant benefits:&nbsp;<ul><li>Unwanted materials containing heavy metals such as lead or cadmium can be prevented from entering subsequent steps in the recycling workflow.&nbsp;</li><li>Materials can be accurately sorted and adequate processes for recovery selected depending on the material type (e.g., LFP vs. MCM).&nbsp;</li><li>The economic value of incoming and outgoing material can be more accurately estimated.</li></ul><h3>4. Waters Corporation: Waters Aura Systems</h3><ul><li>Brochure</li><li><a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/pdf/720009268_7b9ad02cb4.pdf">Full PDF for download</a></li></ul>The presentation introduces the Waters Aura Systems, a family of high-throughput, fluidics-free instruments for the characterization and identification of visible and subvisible particles. All Aura platforms provide particle counting, identification, morphology assessment, and flexible sample volumes ranging from microliters to milliliters. The portfolio includes configurations tailored to different applications: AuraBMI for biologics particle analysis, Aura for particle analysis with identification, <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/2437">AuraPTx</a> for protein formulation development, <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/2438">AuraGT</a> for gene therapy, <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/2439">AuraCL</a> for cell therapy, and <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/2190">Aura+</a> as the most comprehensive platform. The systems are designed for automation-ready operation, straightforward method transfer, and continuity from research through QC.A key feature of the Aura platform is the combination of Backgrounded Membrane Imaging (BMI), Fluorescence Membrane Microscopy (FMM), and Side Illumination Membrane Imaging (SIMI). BMI captures particles on a membrane and subtracts the membrane background to improve particle contrast, while FMM uses fluorescent dyes or conjugated antibodies to distinguish specific particle types. This enables differentiation of protein aggregates, cells, viral capsids, degraded excipients, plastics, fibers, and other contaminants that may look similar based on morphology alone. SIMI adds further information for identifying unlabeled inorganic particles such as glass, fibers, and Dynabeads. Together, these techniques provide more specific particle identification than morphology-based classification alone.The systems are particularly suited to biologics, gene therapy, and cell therapy development. For gene therapy, Aura can evaluate AAV stability, distinguish capsid-related particles, and monitor DNA leakage using SYBR Gold fluorescence, with measurements possible from as little as 5 µL of sample. For cell therapy, the system can differentiate single cells, cell aggregates, protein aggregates, and extrinsic particles. The platform also supports flexible sample volumes and 24- or 96-well membrane formats, allowing the same general approach to be used from sample-limited early development through larger-volume and QC workflows. The brochure reports excellent quantitative linearity across serial dilutions and emphasizes the ability to preserve sample for additional orthogonal analyses.From a technical perspective, Aura Systems provide 100% sampling efficiency, a particle detection and quantitation range above 1 µm, and can handle concentrations above 3,000,000 particles/mL for 1.6 µm particles. Brightfield membrane imaging takes approximately one minute per sample, while fluorescence measurements require about 15–30 seconds per sample. The instruments are compatible with robotic automation and offer different fluorescence-channel configurations depending on the selected Aura model. Overall, the platform is positioned as a comprehensive solution for obtaining quantitative particle counts together with information on particle identity and composition across the development and quality-control lifecycle.

News from LabRulezICPMS Library - Week 36, 2026

Article

Application

Scientists

Environment

Water

The Czech Academy of Sciences (CAS) was established by Act No. 283/1992 Coll. as the Czech successor of the former Czechoslovak Academy of Sciences. It is set up as a complex of 54 public research institutions.

Czech Academy of Sciences

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Pancragen analysis

Targeted HPLC analysis of Pancragen in lyophilised vials and raw API powders, including identity, amount, and peptide purity determination.

The Pancragen Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the peptide purity of Pancragen in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial together with peptide purity. Raw API powders can be evaluated using purity in % (m/m) together with peptide purity.<h4>About Pancragen</h4>Pancragen is a synthetic tetrapeptide with the amino acid sequence Lys-Glu-Asp-Trp (KEDW). It has been studied primarily in relation to pancreatic function and the regulation of pancreatic cells. Preclinical research has examined its effects on pancreatic cell differentiation, glucose metabolism, and age-related changes in endocrine pancreatic function.<h4>Key Features</h4><ul><li>Targeted identification and quantification of Pancragen</li><li>Determination of peptide purity</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial and peptide purity</li><li>Alternative result format for raw API powders includes purity in % (m/m) and peptide purity</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Pancragen</li><li>Sequence: Lys-Glu-Asp-Trp-OH</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for lyophilised samples: mg per vial and peptide purity</li><li>Result format for raw API powders: Purity in % (m/m) and peptide purity</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for Pancragen. It does not automatically screen the sample for other peptides, related compounds, degradation products, contaminants, or undeclared substances.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to protect the sample from moisture.</li><li>The alternative result format for raw API powders includes both purity in % (m/m) and peptide purity.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>TFA Analysis</li><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

PE-22-28 analysis

Targeted HPLC analysis of PE-22-28 in lyophilised vials and raw API powders, including identity, amount, and peptide purity determination.

The PE-22-28 Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the peptide purity of PE-22-28 in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial together with peptide purity. Raw API powders can be evaluated using purity in % (m/m) together with peptide purity.<h4>About PE-22-28</h4>PE-22-28 is a synthetic heptapeptide derived from spadin, an endogenous peptide that inhibits the TREK-1 potassium channel. PE-22-28 was developed as a shorter spadin analogue with the amino acid sequence Gly-Val-Ser-Trp-Gly-Leu-Arg. It has been investigated primarily in preclinical studies focused on TREK-1 inhibition, neurogenesis, synaptogenesis, and antidepressant-like effects.<h4>Key Features</h4><ul><li>Targeted identification and quantification of PE-22-28</li><li>Determination of peptide purity</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial and peptide purity</li><li>Alternative result format for raw API powders includes purity in % (m/m) and peptide purity</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: PE-22-28</li><li>Molecular weight: 789</li><li>Sequence: Gly-Val-Ser-Trp-Gly-Leu-Arg-OH</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for lyophilised samples: mg per vial and peptide purity</li><li>Result format for raw API powders: Purity in % (m/m) and peptide purity</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for PE-22-28. It does not automatically screen the sample for spadin, other related peptides, degradation products, contaminants, or undeclared substances.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to protect the sample from moisture.</li><li>The alternative result format for raw API powders includes both purity in % (m/m) and peptide purity.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>TFA Analysis</li><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Pinealon analysis

Targeted HPLC analysis of Pinealon in lyophilised vials and raw API powders, including identity, amount, and peptide purity determination.

The Pinealon Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the peptide purity of Pinealon in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial together with peptide purity. Raw API powders can be evaluated using purity in % (m/m) together with peptide purity.<h4>About Pinealon</h4>Pinealon is a synthetic tripeptide with the amino acid sequence Glu-Asp-Arg (EDR). It has been studied primarily for its neuroprotective effects and its potential influence on cognitive function. Experimental studies have also examined its effects under conditions of oxidative stress and in relation to age-related changes in the nervous system.<h4>Key Features</h4><ul><li>Targeted identification and quantification of Pinealon</li><li>Determination of peptide purity</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial and peptide purity</li><li>Alternative result format for raw API powders includes purity in % (m/m) and peptide purity</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Pinealon</li><li>Molecular weight: 418</li><li>Sequence: Glu-Asp-Arg-OH</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for lyophilised samples: mg per vial and peptide purity</li><li>Result format for raw API powders: Purity in % (m/m) and peptide purity</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for Pinealon. It does not automatically screen the sample for other peptides, related compounds, degradation products, contaminants, or undeclared substances.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to protect the sample from moisture.</li><li>The alternative result format for raw API powders includes both purity in % (m/m) and peptide purity.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>TFA Analysis</li><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Prostamax analysis

Targeted HPLC analysis of Prostamax in lyophilised vials and raw API powders, including identity, amount, and peptide purity determination.

The Prostamax Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the peptide purity of Prostamax in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial together with peptide purity. Raw API powders can be evaluated using purity in % (m/m) together with peptide purity.<h4>About Prostamax</h4>Prostamax is a synthetic tetrapeptide with the amino acid sequence Lys-Glu-Asp-Pro (KEDP). It has been studied as a short peptide bioregulator, including experimental research involving prostate tissue and chromatin regulation.Available research on Prostamax is primarily experimental and preclinical.<h4>Key Features</h4><ul><li>Targeted identification and quantification of Prostamax</li><li>Determination of peptide purity</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial and peptide purity</li><li>Alternative result format for raw API powders includes purity in % (m/m) and peptide purity</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Prostamax</li><li>Molecular weight: 487</li><li>Sequence: Lys-Glu-Asp-Pro-OH</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for lyophilised samples: mg per vial and peptide purity</li><li>Result format for raw API powders: Purity in % (m/m) and peptide purity</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for Prostamax. It does not automatically screen the sample for other peptides, related compounds, degradation products, contaminants, or undeclared substances.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to protect the sample from moisture.</li><li>The alternative result format for raw API powders includes both purity in % (m/m) and peptide purity.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>TFA Analysis</li><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

PT-141 analysis

Targeted HPLC analysis of PT-141 in lyophilised vials and raw API powders, including identity, amount, and peptide purity determination.

The PT-141 Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the peptide purity of PT-141 in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial together with peptide purity. Raw API powders can be evaluated using purity in % (m/m) together with peptide purity.<h4>About PT-141</h4>PT-141, also known as bremelanotide, is a synthetic peptide that acts on melanocortin receptors in the central nervous system. It has been studied primarily in relation to sexual response and disorders of sexual desire. In the United States, bremelanotide is approved for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women.<h4>Key Features</h4><ul><li>Targeted identification and quantification of PT-141</li><li>Determination of peptide purity</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial and peptide purity</li><li>Alternative result format for raw API powders includes purity in % (m/m) and peptide purity</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: PT-141</li><li>CAS number: 189691-06-3</li><li>Molecular weight: 1025</li><li>Sequence: Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)-OH</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for lyophilised samples: mg per vial and peptide purity</li><li>Result format for raw API powders: Purity in % (m/m) and peptide purity</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for PT-141. It does not automatically screen the sample for other melanocortin-related peptides, degradation products, contaminants, or undeclared substances.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to protect the sample from moisture.</li><li>The alternative result format for raw API powders includes both purity in % (m/m) and peptide purity.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>TFA Analysis</li><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

rHGH fragment or AOD-9604 (HPLC) analysis

Targeted HPLC analysis of rHGH fragment 176-191 and AOD-9604 in lyophilised vials and raw API powders, including identity, amount, and peptide purity.

The rHGH Fragment or AOD-9604 (HPLC) Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the peptide purity of rHGH fragment 176-191 and AOD-9604 in lyophilised vials and raw active pharmaceutical ingredient (API) powders.The analysis can detect and quantify both compounds. For lyophilised samples, results are reported in milligrams per vial together with peptide purity. Raw API powders can be evaluated using purity in % (m/m) together with peptide purity.<h4>About rHGH Fragment and AOD-9604</h4>rHGH fragment 176-191 is a synthetic peptide corresponding to the C-terminal region of human growth hormone. AOD-9604 is a closely related modified analogue that differs at the N-terminal position, where tyrosine is present instead of phenylalanine.Both peptides have been studied primarily in relation to lipid metabolism and their effects on adipose tissue. AOD-9604 was developed from research investigating the metabolic activity of the C-terminal region of human growth hormone.<h4>Key Features</h4><ul><li>Targeted identification and quantification of rHGH fragment 176-191 and AOD-9604</li><li>Detection and measurement of both compounds</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial and peptide purity</li><li>Alternative result format for raw API powders includes purity in % (m/m) and peptide purity</li><li>Several solvent options available for samples with solubility issues</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compounds: rHGH fragment – Somatropin 176-191, AOD-9604</li><li>CAS number – AOD-9604: 221231-10-3</li><li>Molecular weight – AOD-9604: 1815</li><li>Sequence – AOD-9604: H-Tyr-Leu-Arg-Ile-Val-Gln-Cys(1)-Arg-Ser-Val-Glu-Gly-Ser-Cys(1)-Gly-Phe-OH</li><li>CAS number – rHGH fragment: 66004-57-7</li><li>Molecular weight – rHGH fragment: 1799</li><li>Sequence – rHGH fragment: H-Phe-Leu-Arg-Ile-Val-Gln-Cys(1)-Arg-Ser-Val-Glu-Gly-Ser-Cys(1)-Gly-Phe-OH</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for lyophilised samples: mg per vial and peptide purity</li><li>Result format for raw API powders: Purity in % (m/m) and peptide purity</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>rHGH fragment and AOD-9604 samples may have solubility issues during sample preparation.</li><li>Ultrapure water is used as the default solvent. If a stronger solvent is required, 5% acetic acid or DMSO can be selected as an additional service.</li><li>Both DMSO and 5% acetic acid should dissolve AOD samples completely, although the choice of solvent may affect the analytical results. Samples prepared with water have a higher probability of solubility issues.</li><li>This analysis is specifically intended for rHGH fragment 176-191 and AOD-9604. It does not automatically screen the sample for other growth hormone fragments, related peptides, degradation products, contaminants, or undeclared substances.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to protect the sample from moisture.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>TFA Analysis</li><li>Complete Raw Analytical Data</li><li>Solvent: Acetic Acid</li><li>Solvent: DMSO</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Selank analysis

Targeted analysis of Selank in lyophilised vials and raw API powders, including identity, amount, and peptide purity determination.

The Selank Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the peptide purity of Selank in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial together with peptide purity. Raw API powders can be evaluated using purity in % (m/m) together with peptide purity.<h4>About Selank</h4>Selank is a synthetic heptapeptide with the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed as an analogue of tuftsin, a naturally occurring peptide involved in immune regulation.Selank has been studied primarily for its anxiolytic and neuroactive effects, including research focused on anxiety, stress responses, memory, and cognitive function.<h4>Key Features</h4><ul><li>Targeted identification and quantification of Selank</li><li>Determination of peptide purity</li><li>Suitable for lyophilised vials and raw API powders</li><li>Results for lyophilised samples reported in mg per vial and peptide purity</li><li>Alternative result format for raw API powders includes purity in % (m/m) and peptide purity</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Selank</li><li>CAS number: 129954-34-3</li><li>Molecular weight: 752</li><li>Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro</li><li>Result format for lyophilised samples: mg per vial and peptide purity</li><li>Result format for raw API powders: Purity in % (m/m) and peptide purity</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for Selank. Before ordering, please make sure that the sample contains standard Selank and not another version, such as <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/2579">N-Acetyl Selank</a>.</li><li>The analysis does not automatically screen the sample for N-Acetyl Selank, <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/2578">N-Acetyl Selank Amidate</a>, other Selank variants, related peptides, degradation products, contaminants, or undeclared substances.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to protect the sample from moisture.</li><li>The alternative result format for raw API powders includes both purity in % (m/m) and peptide purity.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>TFA Analysis</li><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Semax analysis

Targeted HPLC analysis of Semax in lyophilised vials and raw API powders, including identity, amount, and peptide purity determination.

The Semax Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the peptide purity of Semax in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial together with peptide purity. Raw API powders can be evaluated using purity in % (m/m) together with peptide purity.<h4>About Semax</h4>Semax is a synthetic heptapeptide with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is an analogue of the ACTH(4–10) fragment and has been studied primarily for its neuroprotective effects and its influence on learning, memory, and other cognitive functions.Experimental research has also investigated Semax in relation to cerebral ischemia, neuronal survival, and mechanisms involved in recovery of nervous tissue.<h4>Key Features</h4><ul><li>Targeted identification and quantification of Semax</li><li>Determination of peptide purity</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial and peptide purity</li><li>Alternative result format for raw API powders includes purity in % (m/m) and peptide purity</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Semax</li><li>CAS number: 80714-61-0</li><li>Molecular weight: 814</li><li>Sequence: Met-Glu-His-Phe-Pro-Gly-Pro</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for lyophilised samples: mg per vial and peptide purity</li><li>Result format for raw API powders: Purity in % (m/m) and peptide purity</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for Semax. Before ordering, please make sure that the sample contains standard Semax and not another version, such as<a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/2581"> N-Acetyl Semax</a>.</li><li>The analysis does not automatically screen the sample for N-Acetyl Semax, <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/2580">N-Acetyl Semax Amidate</a>, other Semax variants, related peptides, degradation products, contaminants, or undeclared substances.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to protect the sample from moisture.</li><li>The alternative result format for raw API powders includes both purity in % (m/m) and peptide purity.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>TFA Analysis</li><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Sermorelin analysis

Targeted HPLC analysis of sermorelin in lyophilised vials and raw API powders, including identity, amount, and peptide purity determination.

The Sermorelin Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the peptide purity of sermorelin in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial together with peptide purity. Raw API powders can be evaluated using purity in % (m/m) together with peptide purity.<h4>About Sermorelin</h4>Sermorelin is a synthetic peptide derived from human growth hormone-releasing hormone (GHRH). It acts on GHRH receptors in the pituitary gland and stimulates the release of growth hormone. It has also been used to assess pituitary function.<h4>Key Features</h4><ul><li>Targeted identification and quantification of sermorelin</li><li>Determination of peptide purity</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial and peptide purity</li><li>Alternative result format for raw API powders includes purity in % (m/m) and peptide purity</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Sermorelin</li><li>CAS number: 86168-78-7</li><li>Sequence: H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for lyophilised samples: mg per vial and peptide purity</li><li>Result format for raw API powders: Purity in % (m/m) and peptide purity</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for sermorelin. It does not automatically screen the sample for other GHRH-related peptides, degradation products, contaminants, or undeclared substances.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to protect the sample from moisture.</li><li>The alternative result format for raw API powders includes both purity in % (m/m) and peptide purity.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>TFA Analysis</li><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

SNAP-8 analysis

Targeted HPLC analysis of SNAP-8 in lyophilised vials and raw API powders, including identity, amount, and peptide purity determination.

The SNAP-8 Analysis is a targeted laboratory test designed to confirm the identity, determine the amount, and assess the peptide purity of SNAP-8 in lyophilised vials and raw active pharmaceutical ingredient (API) powders.For lyophilised samples, results are reported in milligrams per vial together with peptide purity. Raw API powders can be evaluated using purity in % (m/m) together with peptide purity.<h4>About SNAP-8</h4>SNAP-8, also known as Acetyl Octapeptide-3, is a synthetic octapeptide used primarily in cosmetic formulations designed to reduce the appearance of facial expression lines and wrinkles.Its activity is associated with modulation of neurotransmitter release involved in muscle contraction, which may help limit the formation and deepening of expression lines.<h4>Key Features</h4><ul><li>Targeted identification and quantification of SNAP-8</li><li>Determination of peptide purity</li><li>Suitable for lyophilised vials and raw API powders</li><li>Analysis by HPLC</li><li>Results for lyophilised samples reported in mg per vial and peptide purity</li><li>Alternative result format for raw API powders includes purity in % (m/m) and peptide purity</li><li>Minimum sample amount of one whole unopened vial with lyophilisate</li><li>Minimum sample amount of 30 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: SNAP-8</li><li>CAS number: 868844-74-0</li><li>Molecular weight: 1075</li><li>Sequence: Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation: Less than 1/20 of the usual dosage per vial</li><li>Result format for lyophilised samples: mg per vial and peptide purity</li><li>Result format for raw API powders: Purity in % (m/m) and peptide purity</li><li>Minimum sample amount for lyophilised samples: One whole unopened vial with lyophilisate</li><li>Minimum sample amount for raw API powders: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for SNAP-8. It does not automatically screen the sample for related peptides, degradation products, contaminants, or undeclared substances.</li><li>For lyophilised samples, one whole unopened vial containing lyophilisate is required.</li><li>Raw API powder should be supplied as at least 30 mg in a sealed glass vial to protect the sample from moisture.</li><li>The alternative result format for raw API powders includes both purity in % (m/m) and peptide purity.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>TFA Analysis</li><li>Complete Raw Analytical Data</li><li>Fentanyl Screening</li><li>Alternative Result Format: Purity in % (m/m)</li><li>Batch Variance Testing</li><li>pH Measurement</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LCMS Screening for Peptide Contamination</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing (TAMC + TYMC)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Products from category Laboratory analyses - page 2

Related content

The Importance of Detecting Per- and Polyfluoroalkyl Substances (PFAS)

Interview: What Drew Postdoc Taťána Gazárková to Analytical Chemistry

News from LabRulezICPMS Library - Week 36, 2026